{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:24:09Z","timestamp":1793157849115,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA128943"],"award-info":[{"award-number":["CA128943"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005322","name":"TE Connectivity plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["23218"],"award-info":[{"award-number":["23218"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.biopha.2025.118384","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T07:07:15Z","timestamp":1754032035000},"page":"118384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["SHP2 is a multifunctional target in anaplastic thyroid carcinoma: Cell intrinsic and immune-dependent anti-tumor effects"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-2639","authenticated-orcid":false,"given":"Maria","family":"Marotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8960-8463","authenticated-orcid":false,"given":"Sara","family":"Zirpoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0186-5431","authenticated-orcid":false,"given":"Nella","family":"Prevete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2537-3228","authenticated-orcid":false,"given":"Antonio","family":"Di Cristofano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-988X","authenticated-orcid":false,"given":"Federica","family":"Liotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-5275","authenticated-orcid":false,"given":"Rosa Marina","family":"Melillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118384_bib1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1073\/pnas.90.6.2197","article-title":"A widely expressed human protein-tyrosine phosphatase containing src homology 2 domains","volume":"90","author":"Ahmad","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118384_bib2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0968-0004(03)00091-4","article-title":"The \u2018Shp\u2019ing news: SH2 domain-containing tyrosine phosphatases in cell signaling","volume":"28","author":"Neel","year":"2003","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.biopha.2025.118384_bib3","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1038\/sj.onc.1203655","article-title":"Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase akt","volume":"19","author":"Hakak","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118384_bib4","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.1038\/sj.onc.1206798","article-title":"The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3","volume":"22","author":"Agazie","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118384_bib5","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1038\/sj.onc.1209728","article-title":"Modulation of \u03b1-catenin tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3","volume":"25","author":"Burks","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118384_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0969-2126(98)00027-6","article-title":"Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2","volume":"6","author":"Barford","year":"1998","journal-title":"Structure"},{"key":"10.1016\/j.biopha.2025.118384_bib7","article-title":"Tyrosine phosphatase PTPN11\/SHP2 in solid tumors - bull\u2019s eye for targeted therapy?","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118384_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117961","article-title":"Formyl peptide receptor 1 signaling strength orchestrates the switch from pro-inflammatory to pro-resolving responses: the way to exert its anti-angiogenic and tumor suppressor functions","volume":"186","author":"Liotti","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2025.118384_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gde.2006.12.011","article-title":"The role of Shp2 (PTPN11) in cancer","volume":"17","author":"Mohi","year":"2007","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.biopha.2025.118384_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.leukres.2004.10.001","article-title":"Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"29","author":"Loh","year":"2005","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biopha.2025.118384_bib11","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2004-10-4057","article-title":"Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia","volume":"106","author":"Xu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118384_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10555-008-9126-y","article-title":"The tyrosine phosphatase Shp2 (PTPN11) in cancer","volume":"27","author":"Chan","year":"2008","journal-title":"Cancer Metastas.. Rev."},{"key":"10.1016\/j.biopha.2025.118384_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cancergencyto.2005.10.003","article-title":"Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors","volume":"166","author":"Martinelli","year":"2006","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.biopha.2025.118384_bib14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1039\/C7MB00151G","article-title":"Covalent inhibition of protein tyrosine phosphatases","volume":"13","author":"Ruddraraju","year":"2017","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.biopha.2025.118384_bib15","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/2211-5463.12493","article-title":"Off-target inhibition by active site-targeting SHP 2 inhibitors","volume":"8","author":"Tsutsumi","year":"2018","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.biopha.2025.118384_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2020.11.007","article-title":"Allosteric SHP2 inhibitors in cancer: targeting the intersection of RAS, resistance, and the immune microenvironment","volume":"62","author":"Kerr","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.biopha.2025.118384_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","article-title":"Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2025.118384_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118384_bib19","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/2159-8290.CD-23-0361","article-title":"SHP2 inhibition sensitizes diverse oncogene-addicted solid tumors to Re-treatment with targeted therapy","volume":"13","author":"Drilon","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118384_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.12688\/f1000research.16677.1","article-title":"Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies","volume":"8","author":"Liotti","year":"2019","journal-title":"F1000Research"},{"key":"10.1016\/j.biopha.2025.118384_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3892\/mco.2023.2695","article-title":"Anaplastic thyroid cancer: pathogenesis, prognostic factors and genetic landscape (Review)","volume":"19","author":"Alhejaily","year":"2023","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118384_bib22","doi-asserted-by":"crossref","first-page":"R319","DOI":"10.1530\/ERC-19-0098","article-title":"Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer","volume":"26","author":"Zaballos","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.biopha.2025.118384_bib23","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3892\/ol.2015.3479","article-title":"Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinoma","volume":"10","author":"Hu","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2025.118384_bib24","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1074\/jbc.M410012200","article-title":"A novel role for Gab1 and SHP2 in epidermal growth Factor-induced ras activation","volume":"280","author":"Montagner","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118384_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.celrep.2018.03.026","article-title":"Shp-2 is dispensable for establishing t cell exhaustion and for PD-1 signaling in vivo","volume":"23","author":"Rota","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2025.118384_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13046-020-01818-1","article-title":"PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2\/Ras\/MAPK signalling in thyroid cancer cells","volume":"40","author":"Liotti","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118384_bib27","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.29360","article-title":"Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1","volume":"66","author":"Li","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2025.118384_bib28","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1408747","article-title":"Blockade of Tumor-Expressed PD-1 promotes lung cancer growth","volume":"7","author":"Du","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.biopha.2025.118384_bib29","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","article-title":"Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor","volume":"59","author":"Garcia Fortanet","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118384_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.celrep.2018.12.013","article-title":"SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-Dependent tumors","volume":"26","author":"Ahmed","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2025.118384_bib31","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/cancers13051139","article-title":"Molecular genetics of follicular-derived thyroid cancer","volume":"13","author":"Macerola","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118384_bib32","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bbrc.2013.09.028","article-title":"Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma","volume":"439","author":"Xu","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2025.118384_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.apsb.2020.07.010","article-title":"Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2025.118384_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00432-025-06097-x","article-title":"SHP2 promotes the epithelial-mesenchymal transition in triple negative breast cancer cells by regulating \u03b2-catenin","volume":"151","author":"Qian","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118384_bib35","doi-asserted-by":"crossref","first-page":"34152","DOI":"10.1074\/jbc.M113.546077","article-title":"SHP2 positively regulates TGF\u03b21-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1","volume":"289","author":"Li","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118384_bib36","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.18632\/aging.204171","article-title":"A pan-cancer analysis confirms PTPN11\u2019s potential as a prognostic and immunological biomarker","volume":"14","author":"Cao","year":"2022","journal-title":"Aging"},{"key":"10.1016\/j.biopha.2025.118384_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107966","article-title":"Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials","volume":"230","author":"Song","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118384_bib38","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1038\/onc.2014.441","article-title":"Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8\u2013Akt\u2013Slug pathway","volume":"34","author":"Visciano","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118384_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/stem.2492","article-title":"Interleukin-8, but not the related chemokine CXCL1, sustains an autocrine circuit necessary for the properties and functions of thyroid cancer stem cells","volume":"35","author":"Liotti","year":"2017","journal-title":"Stem Cells"},{"key":"10.1016\/j.biopha.2025.118384_bib40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3892\/or.2014.3201","article-title":"Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma","volume":"32","author":"Hu","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2025.118384_bib41","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/hep.28919","article-title":"Shp2 promotes liver cancer stem cell expansion by augmenting \u03b2-catenin signaling and predicts chemotherapeutic response of patients","volume":"65","author":"Xiang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2025.118384_bib42","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114089","article-title":"Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth","volume":"13","author":"Wang","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biopha.2025.118384_bib43","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","article-title":"SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models","volume":"8","author":"Fedele","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118384_bib44","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.7150\/jca.83853","article-title":"Early combined SHP2 targeting reverses the therapeutic resistance of vemurafenib in thyroid cancer","volume":"14","author":"Ma","year":"2023","journal-title":"J. Cancer"},{"key":"10.1016\/j.biopha.2025.118384_bib45","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit t cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2025.118384_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay4458","article-title":"Molecular mechanism of SHP2 activation by PD-1 stimulation","volume":"6","author":"Marasco","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2025.118384_bib47","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/s41598-021-80999-x","article-title":"SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms","volume":"11","author":"Wang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118384_bib48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.apsb.2021.08.006","article-title":"Allosteric inhibition reveals SHP2-mediated tumor immunosuppression in colon cancer by single-cell transcriptomics","volume":"12","author":"Gao","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2025.118384_bib49","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1089\/thy.2011.0030","article-title":"Establishment and characterization of cell lines from a novel mouse model of poorly differentiated thyroid carcinoma: powerful tools for basic and preclinical research","volume":"21","author":"Dima","year":"2011","journal-title":"Thyroid"},{"key":"10.1016\/j.biopha.2025.118384_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.biopha.2025.118384_bib51","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/s41418-017-0044-9","article-title":"eIF2\u03b1 phosphorylation is pathognomonic for immunogenic cell death","volume":"25","author":"Bezu","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2025.118384_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jim.2019.04.007","article-title":"An optimized protocol to determine the engulfment of cancer cells by phagocytes using flow cytometry and fluorescence microscopy","volume":"470","author":"Nam","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.biopha.2025.118384_bib53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2159-8290.CD-21-0369","article-title":"Combined inhibition of SHP2 and CXCR1\/2 promotes antitumor T-cell response in NSCLC","volume":"12","author":"Tang","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118384_bib54","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.apsb.2018.08.009","article-title":"SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade","volume":"9","author":"Zhao","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2025.118384_bib55","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1158\/0008-5472.CAN-19-3038","article-title":"Allosteric inhibition of SHP2 stimulates antitumor immunity by transforming the immunosuppressive environment","volume":"80","author":"Quintana","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118384_bib56","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118384_bib57","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1089\/thy.2012.0302","article-title":"American thyroid association guidelines for management of patients with anaplastic thyroid cancer","volume":"22","author":"Smallridge","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.biopha.2025.118384_bib58","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-018-0903-0","article-title":"Therapeutic advances in anaplastic thyroid cancer: a current perspective","volume":"17","author":"Saini","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2025.118384_bib59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic braf V600\u2013Mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118384_bib60","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11864-020-00776-2","article-title":"Contemporary management of anaplastic thyroid cancer","volume":"21","author":"Alobuia","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.biopha.2025.118384_bib61","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause noonan syndrome","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2025.118384_bib62","first-page":"247","article-title":"Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor","volume":"12","author":"Zhi","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118384_bib63","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/0008-5472.CAN-14-1215","article-title":"PD-1\/SHP-2 inhibits Tc1\/Th1 phenotypic responses and the activation of t cells in the tumor microenvironment","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118384_bib64","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1158\/2767-9764.CRC-22-0117","article-title":"Tumor cell\u2013autonomous SHP2 contributes to immune suppression in metastatic breast cancer","volume":"2","author":"Chen","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.biopha.2025.118384_bib65","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2025.118384_bib66","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1038\/onc.2014.309","article-title":"The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis","volume":"34","author":"Prevete","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118384_bib67","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1293213","article-title":"Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways","volume":"6","author":"Prevete","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.biopha.2025.118384_bib68","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.biopha.2025.118384_bib69","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3390\/cancers11101582","article-title":"CAF-1 subunits levels suggest combined treatments with PARP-Inhibitors and ionizing radiation in advanced HNSCC","volume":"11","author":"Morra","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118384_bib70","doi-asserted-by":"crossref","first-page":"35946","DOI":"10.18632\/oncotarget.16412","article-title":"Multiple anti-tumor effects of reparixin on thyroid cancer","volume":"8","author":"Liotti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118384_bib71","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cell.2016.12.026","article-title":"Nuclear localization of mitochondrial TCA cycle enzymes as a critical step in mammalian zygotic genome activation","volume":"168","author":"Nagaraj","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118384_bib72","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.4078","article-title":"The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death","volume":"22","author":"Pozzi","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118384_bib73","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jaci.2006.09.027","article-title":"Differentiation of monocytes into macrophages induces the upregulation of histamine H1 receptor","volume":"119","author":"Triggiani","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2025.118384_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003561","article-title":"Development of a pHrodo-Based assay for the assessment of in vitro and in vivo erythrophagocytosis during experimental trypanosomosis","volume":"9","author":"Stijlemans","year":"2015","journal-title":"PLOS Negl. Trop. Dis."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:34:33Z","timestamp":1772786073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225005785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":74,"alternative-id":["S0753332225005785"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118384","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SHP2 is a multifunctional target in anaplastic thyroid carcinoma: Cell intrinsic and immune-dependent anti-tumor effects","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118384"}}